Boyu Capital Said to Weigh Sale of Medical Device Maker Quasar

This is a notable data point for Asia private equity, where exits have been slow and a $1 billion-plus medical device sale would signal renewed appetite for healthcare assets. It matters most to Boyu's limited partners and to other sponsors holding similar Singapore-based manufacturing platforms, since a successful process would set a comparable benchmark. The open question is whether preliminary adviser talks translate into a formal sale, or whether valuation gaps keep the process exploratory.